Discover a new adventure

Mucosinix Pharm

Yale University

Mucosinix has a new class of antibiotics which have not been shown to trigger resistance in MRSA culture. This new antibiotic class shows promise as a treatment for multidrug resistant microbes.

My Gene Counsel

Yale University

My Gene Counsel has created scalable, digital technology that pairs specific genetic test results with accurate, continuously updating information for clinicians and consumers. By helping patients and doctors become aware of the implications of genetic testing results, My Gene Counsel can help improve patients' lives and avoid unnecessary risky medical procedures.

Gateway Bio

Duke University

Gateway Bio is developing an innovative “PEG-like” drug conjugation technology that eliminates the antigenicity issues surrounding PEGylation today. Gateway Bio was specifically formed to translate several scientific breakthroughs from the lab of Professor Chilkoti at Duke University into commercially viable products and processes by combining the expertise of the academic scientists closest to these technologies with the business acumen of experienced start-up professionals. The initial core technology of Gateway Bio is based on several key patents on POEGMA conjugates that have been successfully licensed from Duke by Gateway Bio. Our novel method of creating PEG-like conjugates could be applied to generics, existing drugs, newly developed drugs or any of the PEGylated pharmaceuticals currently on the market. There are currently 15 FDA-approved peglyated drugs, with dozens more in clinical trials. Sales of the two most successful pegylated products, Pegasys and Neulasta, exceeded $5 billion in 2011.

Lkit Therapeutics

Yale University

A Novel Chemical Approach to Target p53 Mutation in Human Cancer. There is currently no treatment that specifically targets p53 mutation, the most common genetic abnormality associated with cancer. Loss of p53 tumor suppressor function provides cells with a proliferative advantage but renders them susceptible to metabolic stress. We have developed potent and selective inhibitors for PIP4K2A and PIP4K2B that regulate cell metabolism and are essential for the growth of p53-deficient tumor.

Pangolin Therapeutics

Yale University

Numerous clinical trials in amyloidosis have failed as a result of misdirected focus on amyloid states of disease-causing proteins. Pangolin Therapeutics’ (PTx) small-molecule platform, termed Pangomers™, was developed to address this deficiency. The Pangomer™ core structure enables selective targeting of pre-amyloid, toxic oligomers (PAOs). Here, we seek to address Multiple System Atrophy (MSA), an aggressive, orphan-indicated form of Parkinson's for which there are no approved therapeutics. Our pilot efforts have identified and validated a strategy for development of Pangomer™ analogues that neutralize PAOs from MSA. Additional funding will allow execution of this strategy delivering a lead molecule for pre-clinical advancement.

MyophonX

Cornell University

Solutions for silent speech production lack innovation, cultural acceptability, and often involve invasive surgery. MyophonX is cutting-edge wearable technology for silent communication, with applications to stroke and laryngectomy patients as well as voice searching.

Princeton NuEnergy

Princeton University

Lithium-ion (Li-ion) batteries are used in many products such as electronics, toys, wireless headphones, handheld power tools, small and large appliances, electric vehicles, and electrical energy storage systems. If not properly managed at the end of their useful life, they can cause harm to human health or the environment. Princeton NuEnergy is revolutionizing the material supply chain with its patented low-cost process for producing high quality cathode active materials from spent lithium ion batteries. With successful operation of our lab scale plant and strong relationships throughout the electric vehicle supply chain we are building out our team to execute our production scale manufacturing plants starting in 2021.

Selective Stents

Yale University

Currently available drug-eluting stents release drugs such as sirolimus or everolimus, which stop smooth muscle growth to prevent in-stent restenosis. However, they also block endothelial cell growth and create risk of thrombosis and mandate long-term antiplatelet medication. Nevertheless, yearly, 10% of these stents fail due to late thrombosis or stenosis. We discovered a drug combination (Fas ligand and nitric oxide) which inhibits smooth muscle growth more potently than sirolimus or everolimus but does not affect endothelial growth. This project will lead to the development of a next generation DES with a unique biologically selective effect on smooth muscle and endothelium.

DAR-901: TB Vaccine Booster

Dartmouth College

Tuberculosis (TB) is the leading infectious disease cause of death worldwide, including in persons with HIV infection. Drug-resistant TB, an increasingly global epidemic, requires prolonged treatment with toxic, expensive drugs. BCG, the only vaccine currently in use for the prevention of TB, is very effective for the first few years of life but loses efficacy after 10-15 years. The only new vaccine to have shown efficacy in humans in a fully-powered Phase 3 trial is the booster vaccine being developed by investigators at Dartmouth College. DAR-901 is the most advanced and promising candidate in the global portfolio. Pre-clinical studies include a tuberculosis challenge study indicating DAR-901 is superior to the BCG booster vaccine.

Aromha

Harvard University

Smell loss is an early indicator of infectious and neurodegenerative disorders. In COVID-19, for example, objective smell loss may occur in >90% of patients. Though molecular (PCR) tests are effective in diagnosing SARS-CoV-2 infection, with moderate sensitivity and high specificity, they typically are costly (>$50), with long turnaround times (up to 5-7 days) and have not been as effective in controlling asymptomatic spread. The Aromha Smell Test complements molecular tests with high sensitivity and negative predictive value and can be scaled quickly to provide an important new tool to prevent community spread of COVID, with an at-home, non-invasive, safe, and cost-effective screening test that provides instantaneous results. This platform technology, developed based on 20 years of olfactory research at Harvard, can also be utilized to provide an early signal and improve care in critical neurodegenerative diseases such as Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury.

ClostraBio

University of Chicago

ClostraBio is a preclinical-stage pharmaceutical company creating new medicines to treat diseases resulting from intestinal barrier dysfunction, especially those caused by shifts to the microbiome. ClostraBio's first indications are in the treatment and prevention of food allergy, initially peanut allergy, and ClostraBio recently began a program in colitis. ClostraBio has licensed a proprietary drug delivery platform, developed by the ClostraBio co-founders, from the University of Chicago and are using this platform for oral delivery of small molecules and metabolites derived from the microbiome to the GI tract. ClostraBio's founding scientific team are key opinion leaders and world's experts in food allergy, the microbiome, immunology and immuno-engineering, drug delivery, and polymer chemistry. ClostraBio is seeking a Chief Executive Officer and Chief Medical Officer.

Oath Endovascular

Yale University

Our technology combines novelty in bioabsorbable stent technology and regenerative medicine. Our team has unrivaled experience in both technologies and have taken the project funded by the European commission to an advanced stage in development. Our initial therapeutic target will be peripheral vascular disease where there is no comparative technology in use or development. Beyond this, there is potential widespread application of the device and concept to the heart, brain, liver and cancer treatments where the combined technology can provide a unique state of the art therapeutic system.

synLubricin

Cornell University

Lubrication is critical in biology for tasks such as joint flexing and eye movement, but aging and disease can reduce natural lubrication. Current lubrication solutions either exhibit a short half-life (such as cortisone and hyaluronic acid) or poor long-term bio-compatibility (such as exogenous lubricants like glycerin-mineral oil), leaving a market opportunity to develop a durable, bio-compatible lubricant. synLubricin is a stable, and scalable, long-term bio-lubricant for joints, eyes, and medical devices. synLubricin has been developed in FDA-approved human cell culture systems and is able both to resist cellular adhesion and lubricate biological surfaces, such as cartilage. synLubricin is searching for a co-founder to help develop this venture opportunity.

Immunaxis

Yale University

Glioblastoma multiforme (GBM) is an incurable form of brain cancer with no effective therapy. Unlike other organs, brain has limited immune surveillance because of blood brain barrier and lack of lymphatics drainage. Immunaxis proposes to exploit the meningeal lymphatic vessels to overcome immune barrier to achieve successful treatment of glioblastoma.

TildenBio

University of California, Berkeley

Mammalian cell tissue culture is critical to biomedical research and to the production of many blockbuster drugs. Animal-sourced sera provide the growth factors and cytokines that are essential for tissue culture. After an initial $1.5 million investment, TildenBio's photosynthetic platform is suited to producing biomedical proteins economically, simply, and at large scale. We have achieved expression levels of over 20% of total protein. TildenBio’s technology is simultaneously applicable to a number of markets, including the diagnostic market, edible vaccine market, industrial enzyme market, and possibly next-generation antibiotic markets. With an initial beachhead focused on producing low-cost growth factors and cytokines as replacements for animal-sourced tissue culture sera, TildenBio is searching for a CEO to lead the team into its next chapter.

Inleptin Therapeutics

George Washington University

Note: No company is formed yet. Seeking entrepreneur to lead. Opioids remain an indispensable treatment for severe pain despite increased risk for obese patients with tolerance. Of particular concern is opioid-induced respiratory depression (OIRD), especially during sleep, due to comorbid obstructive sleep apnea common in obese patients. Naloxone is the only drug available that can reverse the adverse effects of opioids and prevent death. However, naloxone has limited use because it reverses analgesia and induces withdrawal. A preventive treatment for sleep-related OIRD that does not affect analgesia or induce withdrawal is critical in patients with obesity. GW and JHU researchers found that intranasal leptin can reverse morphine-induced apneas, hypoventilation, and upper-airway obstruction while enhancing analgesic effects in mice with obesity.

Carbacyclix

Dartmouth College

Natural product molecules (and derivatives) are important for the development of modern drugs, as they play a vital role in the pipeline for new therapeutics. For example, >100 FDA-approved drugs are derived from tetracyclic terpenoids, which can be metabolized by the body into steroids. Despite this success, there remain considerable limitations to broad medicinal exploitation of the class due to lingering scientific challenges associated with compound availability. Carbacyclix has developed a concise asymmetric route to forging natural and unnatural (enantiomeric) C19 and C20 tetracyclic terpenoid skeletons suitable to drive medicinal exploration. While efforts have been focused on establishing the chemical science, early investigations reveal that the emerging chemical technology can deliver compositions of matter that are potent and selective agonists of the estrogen receptor beta.

SimpEL

Washington University in St. Louis

An implantable, bone-anchored sympathetic nerve stimulator that can be used for treatment of chronic pain, hypertension, asthma, hyperactive bladder, and many other conditions.

Immplacate

Columbia University

Patients with acute and chronic immune disorders have an increased risk of death and a reduced quality of life. Mesenchymal stem cells (MSCs) show promise for effectively treating immune disorders and clinical trials have shown few side effects of MSCs, however naïve MSCs alone are not sufficiently effective. Immplacate will provide an effective and safe solution, allowing patients to return to a lifestyle closer to before their onset of disease, through the use of its proprietary process of educating mesenchymal stem cells (EMCs). Immplacate’s novel approach will utilize its EMC therapy where 100% of the cells are therapeutic from the moment they are injected. Immplacate is founded by Drs. Gordana Vunjak-Novakovic and Holly Wobma.

LiMAX Biosciences

Harvard University

Wounds outside and inside the body are common and can be devastating. Wound adhesives have not been able to compete with suturing due to lack of strength and flexibility. LiMAX has developed a gel adhesive using biomimicry which is able to outperform existing medical adhesives in strength and flexibility. LiMAX is focusing on the application to skin first, but the applications of the technology span many tissues.

AbSeek Bio

Vanderbilt University

The human immune system participates in complex interactions with virtually all other systems in the body. In particular, the B-cell component of the adaptive immune response plays a role in various disease settings, including infectious disease, cancer, autoimmunity, cardiovascular, hematologic, neurologic diseases, and others. In addition, antibodies (a product of B cells) are effectively used in diagnostics, therapy, and prevention. To address these significant challenges with current technologies for B cell characterization and antibody discovery, we recently developed a novel technology that, for a given sample, enables the mapping of antibody sequence to antigen specificity from a single high-throughput experiment for a large number of antigens and B cells at a time.

Carver Biosciences

Princeton University

Broad-spectrum antiviral therapies do not exist, tragically hindering our ability to respond to viral outbreaks and pandemics. We need new approaches to treat these diseases, as existing therapeutics are very narrow-spectrum and take many years to develop. Carver Biosciences is a startup company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The underlying technology, CARVER, was developed by founder Cameron Myhrvold during his time as a postdoc at the Broad Institute of MIT and Harvard and was published in Molecular Cell in 2019. Carver recently closed a seed round and is looking to expand it's team.

AquaDrive

Columbia University

The top 5 drugs sold are delivered by injection, 3 are biologics. Due to discoveries in fields like immuno-oncology, more of these high revenue drugs are biologics. Biologic drugs present a big promise, but they are met with a big problem: They are usually macromolecules, a fact that makes their formulations highly viscous and current injection devices require long injection times and larger gauge needles. The net result for patients is pain and discomfort and therefore reduced acceptance and compliance for treatments. AquaDrive (pka Inviscable) is developing a high performance actuator that could drive formulations 7x more viscous than any other technology currently available on the market, reducing the number of injections by half while minimizing device failure due to the robustness of the actuator at the core of the device.

GreenNanomed

Yale University

A Natural Nanoparticle Platform for Drug Delivery to the Brain. Drug delivery to the brain is major challenge because of the existence of the blood brain barrier (BBB). Here we present a novel natural nanoparticle platform that can overcome the BBB and enable efficient drug delivery to the brain. We demonstrate a lead product that is readily translated into clinical applications for effective stroke treatment.

Bacchus Therapeutics

Stanford University

Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of MYC is virtually unmatched, making MYC one of the most frequently deregulated oncogenes in human tumors, including, liver, kidney, CNS, hematopoietic, breast, prostate, lung and GI tumors. Human studies and animal models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers. Our founders, Drs. Gouw and Felsher, discovered that MYC regulates the aberrant lipid metabolism of tumors and that inactivation of key lipid enzymes results in regression of tumors.

TUG-C Obesity Target

Yale University

While obesity is a growing worldwide epidemic, there are few effective treatments. This technology aims to inhibit a degradation pathway, therefore increasing heat and calorie burn in patients with obesity.

Xscape Photonics

Columbia University

Datacenters are a critical component of the modern internet, responsible for processing and storing tremendous amounts of data in the “cloud.” Datacenters also provide the computational power needed for handling “big data,” a growing segment of the U.S. economy. Xscape is making the next-generation photonic communication networks for high-performance computation. Such networks are crucial for data centers, machine learning, and artificial intelligence. Our technology is based on our world-leading photonic-chip technology combined with massive frequency-division multiplexing, which allows for ultrahigh bandwidth communications up to 25 times faster than products currently on the market. This scalable technology is smaller and less expensive than current products and requires less power. The scientific founders are seeking a dedicated CEO to build the company.

IPF-ML Diagnostics

Yale University

Idiopathic pulmonary fibrosis (IPF) is a deadly chronic lung disease with median survival of 3 years and with a worse prognosis than lung cancer. 6 million people worldwide are affected - 200,000 in North America are affected with 45,000 dying each year. The progressive decline of lung function characterizing it is interspersed with unpredictable disease flares called acute exacerbations of IPF (AE-IPF) that accelerate lung function loss and increase morbidity and mortality. The annual incidence of AE is up to 20% with a mortality ranging from 35-90%, demonstrating the severity of IPF disease progression and the importance for active disease monitoring (ER visits and hospital stays can amount to >$11,500 per case). Current therapeutics are unable to predict how an individual patient will progress and whether they will respond to available interventions. The market size for biomarker chip detection of PIF is ~$3B, underscoring the need for a more robust treatment for PIF.

BioBina

Columbia University

Effective treatment of abdominal and thoracic cancers requires a more targeted and improved penetration of therapeutics in order to reduce off-target side effects and increase efficacy. BioBina has developed a treatment strategy which utilizes existing radiation therapy with an increased specificity and penetration of the therapeutic to the affected tissue. The technology has been developed for ovarian cancer and has the potential to be extended to a multitude of abdominal and thoracic cancers.

MAEGI Medicine

Yale University

MAEGI is a new class of immunotherapy which activates a customizable group of genes for personalized cancer treatment. It can be used as an off the shelf cancer treatment or a highly customized treatment specific to certain cancer types or patients.

TKine Therapies

Yale University

Therapeutic interventions for Angioimminoblastic T cell lymphoma have limited efficacy. TKine Therapies has identified a promising target CXCR5 which is involved in metastasis and found on the cell surface in T cell lymphomas. They have developed a small molecule inhibitor of CXCR5 which is potent at nanomolar concentrations in vitro and which has demonstrated activity in a mouse model of CXCR5-expressing T cell lymphoma.

ACIS

Yale University

The Accurate Cell Injection System (ACIS), a new technology for high throughput cell injections. In the world of IVF and cell injection in general, visual input is unreliable. ACIS can provide reliable and real-time confirmation of cell penetration & viability independent of visualization by detecting cell membrane electrical resistance. ACIS is easily integrated into any cell injection system.

TAIRIS

University of Pennsylvania

There are 230 million surgeries performed per year worldwide. Surgical experience is the primary factor dictating outcome of each operation. However, surgical experience is not quantifiable, not accessible as a data source, and not easily distributable between users. This leads to variability in outcomes, complications, inefficiency, and high costs in surgical care delivery. What if an artificial intelligence (AI) platform could be designed that would quantify and learn from surgical experience, then customize and distribute tailored information back to all surgeons in real-time?

AI-MI SPECT

Yale University

Artificial Intelligent Medical Imaging: Safer, Faster, Cheaper Medical Imaging Enabled by AI and Deep Learning. The clinical challenges in radiology frequently highlighted are the large radiation doses, long imaging times, expensive hybrid imaging equipment, and expensive room shielding. AI-MI combined with SPECT (Single Photon Emission Computed Tomography) aims to provide equivalent diagnostic accuracy without CT, at lower doses, at lower cost, and faster - allowing for higher throughput through radiology.

AimRNA

University of California, Davis

AimRNA’s novel RNA bioengineering technology produces a wide variety of biologic RNA molecules through a large yield, cost effective bacterial fermentation process, among them a number of leads have been demonstrated efficacy and safety for the treatment of lung and liver cancer in animal models. We have been awarded with SBIR Phase I grant in 2018, and we are currently raising $500,000 to fund IND-enabling studies and $7 million for clinical investigations.

3RT Innovations

University of California, San Diego

Traumatic brain injury (TBI) contributes to approximately one-third of all injury-related deaths in the United States, with total direct and indirect costs estimated in excess of $76 billion. TBI is also the leading environmental risk factor associated with the development of chronic traumatic encephalopathy (CTE), a progressive degenerative disorder of the brain. Given the extensive public health burden, the lack of any approved therapies to modify the disease course for CTE continues to represent a critical unmet need. 3RT Innovations is a start-up founded in 2019 to address this need. We are currently developing a novel, brain penetrating antibody for the treatment of CTE. The neuropathology of CTE is characterized by abnormal aggregations of tau proteins in the neocortex with an organized filament structure comprised of three-repeat (3RTau) and four-repeat tau (4RTau). This organized filament structure is unique as it is found only in CTE and not in other tauopathies such as Alzheimer’s Disease.

PrevPanc

Stanford University

PrevPanc is developing an improved prophylactic against pancreatitis caused by endoscopic retrograde cholangiopancreatography (ERCP), by targeting two key inflammatory pathways. Post-ERCP pancreatitis can be life-threatening, excruciatingly painful, and costly. PrevPanc is developing a more effective and practical treatment to prevent pancreatitis, with significant improvements beyond current options of indomethacin, stenting, and IV hydration. PrevPanc's therapy is a combination of a calcineurin inhibitor combined with indomethacin to target two distinct inflammatory pathways, achieving higher effectiveness than the current standard of care with minimal change in post-procedure care.

Pepper Bio

Massachusetts Institute of Technology

Pepper Bio has developed the world’s first transomic drug discovery platform. We integrate phosphoproteomics, proteomics, transcriptomics, and genomics. This whole-stack solution to common drug discovery challenges reveals actionable insights that others miss to questions ranging from target ID to patient stratification using a global, dynamic, and causal approach. We’ve developed a full-stack drug discovery platform (PROSPER) to tackle complex, untreatable diseases.

FloraPulse

Cornell University

The FloraPulse system is a microchip tensiometer (microtensiometer) that is embedded into the tree woody tissue and directly measures the water status, known as water potential. Because the measurement is taken directly inside the water-carrying tissue, readings are very accurate and reliable. You receive daily midday stem water potential readings, along with science-backed irrigation recommendations. Since 2017, we raised $1.2M in non-dilutive SBIR research awards to develop microT, and successfully field tested the product in almond, grape and prune commercial orchards and vineyards. In 2019-2020, we received $50k in customer deposits and sold the first 60 subscriptions ($90k) to 15 customers in the US, Chile and Australia. Customer feedback has been very positive. We are looking to hire a seasoned CEO to help the company raise funds, build partnerships, and continue increasing product sales in the US and abroad.

Enviar Therapeutics

Columbia University

Current delivery platforms for RNA and gene editing technologies induce off-target effects and fail to specifically target tissue types. Led by Columbia’s Dr. Fatemeh Momen-Heravi and Dr. Akiva Mintz, the Enviar team has recently developed a novel customizable delivery platform—called SafeExo—based on engineered exosomes. Exosomes naturally carry biomacromolecules including different RNAs (mRNAs, regulatory miRNAs, etc.), DNAs, lipids, and proteins and can deliver their cargoes to the recipient cells, elicit functions, and mediate cellular communications. SafeExo is the first engineered exosome platform capable of eliminating endogenous nucleic acids, which greatly reduces off-target effects. SafeExo is further optimized to enhance RNA stability, CRISPR efficacy, target uptake and specific cell/tissue delivery of large payloads, such as targeted CRISPR/CAS gene editing machinery and RNAi therapeutics. This platform has the potential to treat new diseases and improve current therapies.

Reach Neuro

University of Pittsburgh

Stroke is an incredibly pervasive problem that directly affects one quarter of the world’s population. Unfortunately, many of these people are told they will never regain functional use of their arm or hand. With Reach, they will. One of our patients was able to cut food with a fork and knife and feed herself for the first time in 9 years since having her stroke. In contrast to existing assistive tools such as functional electrical stimulation, Reach’s device allows the user full control over complex and naturalistic movements. Advantages of the technology: • Assists movements in all upper limb joints • Restores naturalistic and voluntary movements • Immediate improvements • Assists users in performing tasks of daily living • Eligible for chronic stroke patients even years after their stroke • Uses standard implant device and surgical procedure • Does not require donning and doffing bulky equipment

Endovascular Retrieval Device

Yale University

Inferior vena cava (IVC) filters are implantable devices that prevent clots from embolizing from the legs to the lungs. Even though the FDA recommends retrieval of the filter when the risk of VTE or bleeding has resolved, IVC filter removal is technically challenging and sometimes impossible because of tilt and scarring. The team has developed and patented a device that can safely retrieve filters in any configuration.

Cadence Shoe Technologies

University of California, Santa Barbara

Foot Drop is a mobility disorder prevalent in patients that is a common result of neurological injuries or diseases such as stroke cerebral palsy, MS or brain tumors. Foot drop is characterized by the inability to lift the toes toward the shin. It inhibits the rhythmic swing phase of the gait, increasing the probability of falls and manifests in abnormal gait patters that inhibit mobility and create imbalances and stress. Currently, there is not a rehabilitative solution that is cost effective and practical for every day independent use. Dr. Tyler Susko has developed a shoe that provides a low-friction out-sole during the swing phase of the gait, and a high-friction out-sole during the stance phase of the gait. The design can be used on any style shoe. Preliminary pilot studies with impaired adults have shown immediate gait improvement.

Carrisan Technologies

University of California, Davis

Foodborne illness is a significant health and economic problem globally. Cross-contamination of food by pathogens via surfaces of food processing equipment is a leading risk factor in foodborne disease outbreaks. Antimicrobial coatings that make food contact surfaces self-sanitizing have potential to reduce cross-contamination and represent a $2.3B market opportunity. Despite that promise, the antimicrobial coating technology available for food contact surface applications is severely limited by a lack of food-grade coatings, lack of efficacy in high volume/organic matter environments, difficult application, high cost and challenges in use with legacy equipment. We have developed novel antimicrobial coatings to make food contact surfaces self-sanitizing to prevent cross-contamination. The coatings are made of food-grade, FDA GRAS materials. They are safe, effective, low-cost, environmentally friendly and useable on legacy equipment. The underlying technology was developed at University of California-Davis.

AgingSense

University of Pennsylvania

AgingSense is a company focused on developing technological solutions to complex problems of aging to improve quality of life of older adults. The first technological solution being developed is Heart Failure Monitoring Socks. This wearable sock technology monitors persons with heart failure for exacerbations as well as response to treatment. The socks monitor for changes related to heart failure specifically, leg edema, using stretch sensors, and fatigue using actigraphy and gyroscopes. Data is sent by blue tooth to an app which is run through an algorithm in a secure cloud that triggers a message to the individual with HF, a trusted other and/or their provider of changes in their condition. The ultimate goal is to improve heart failure management to keep persons with heart failure home and out of the hospital with a better quality of life.

NeuroProbe

Yale University

Neuro-ICUs are faced with frequent shortcomings in maintaining brain care. Access requires one large or multiple smaller access points and devices require multiple external interface devices & monitors that frequently face challenges in the synchronization, analysis, and interpretation of data. The NeuroProbe System is a portable multimodal implant (EEG, temperature, oxygen, pressure, blood flow) that offers equal or better sensitivity via a single point of access along with synchronized sensor data via a single output connection. NeuroProbe has completed FDA pre-submission and developed prototype NeuroProbe and NeuroMonitor devices, with a system prototype demonstration ongoing in Summer 2019.

VaxNewMo

Washington University in St. Louis

VaxNewMo’s goal is to be the next bioconjugate vaccine platform company. It is seeking a business co-founder to help shape a clinical development, fundraising, and partnership strategy that can maximize its impact and value

FatesEDS

Stanford University

FatesEDS is developing a compact, sensitive X-ray differential phase contrast (DPC) imaging system that improves field of view, increases fringe visibility and shortens imaging times. This system surpasses the performance of 3-grating DPC systems used today with a single grating that is combined with a specialized X-ray source and detector. By eliminating the two expensive grating components, the overall size and potential cost of the system is reduced along with enabling a single-step image acquisition with a field-of-view of ~35 degrees and fringe contrast ~25%. FatesEDS is focused on developing a next-generation baggage inspection system to identify hazardous materials, with a potential medical imaging application. FatesEDS is seeking an experienced entrepreneur to help lead the commercialization of this system.

Apeiros Bioscience

Yale University

Our goal is to develop a new cancer drug that is an antibody drug conjugate (ADC). It targets the pi subunit of the Gamma Aminobutyric Acid Receptor (GABRP) that is aberrantly expressed in a broad range of solid tumors. The target was discovered by the Pusztai lab and a provisional patent application has been submitted. We will use the Blavatnik Fund to perform affinity maturation, generate humanized anti-GABRP antibody conjugated to emtansine and assess the anti-tumor activity in vitro and in vivo.